Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News AIM ImmunoTech Inc AIM

Healthcare Biotechnology
AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. Its flagship products are Ampligen (rintatolimod), a drug of large macromolecular double-stranded ribonucleic acid molecules to treat chronic fatigue syndrome; and Alferon N Injection... see more

Current News (NYSEAM:AIM)

AIM ImmunoTech Announces Release of the Next CEO Corner Segment

GlobeNewswire 6 days ago

AIM ImmunoTech to Participate in Live 'Fireside' Chat on Virtual Investor Closing Bell Series

GlobeNewswire December 1, 2025

AIM ImmunoTech Reports Third Quarter 2025 Financial Results and Highlights Continued Progress Across Pipeline with Strategic Focus on Pancreatic Cancer Clinical Program

GlobeNewswire November 18, 2025

AIM ImmunoTech Details New UPMC Abstract on Completed Clinical Trial Involving Ampligen's Synergistic Potential in the Treatment of Advanced Recurrent Ovarian Cancer

GlobeNewswire November 10, 2025

AIM ImmunoTech Announces Late Breaking Abstract from University of Pittsburgh Medical Center Accepted for Presentation at the 40th Annual Society for Immunotherapy of Cancer (SITC) Meeting

GlobeNewswire November 4, 2025

AIM ImmunoTech Announces European Patent Office Grants Patent Covering Ampligen® (Rintatolimod) for Use in the Treatment of the Post-COVID Condition of Fatigue

GlobeNewswire November 3, 2025

AIM ImmunoTech to Attend the 2025 Maxim Growth Summit

GlobeNewswire October 20, 2025

AIM ImmunoTech Secures Patent in Japan Through 2039 for Novel Cancer Therapy Combining Ampligen® (Rintatolimod) with Checkpoint Inhibitors

GlobeNewswire September 25, 2025

AIM ImmunoTech Announces Publication of Journal Article On the Positive Effect of Ampligen and Interferon-Alpha on Tumor Growth

GlobeNewswire September 22, 2025
View More News ››

Opinion & Analysis (NYSEAM:AIM)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NYSEAM:AIM)

Buy buddy buy.

Because this stock is going up big-time today so good luck to all shareholders
coolfooldumbguy - July 28, 2025
View more Bullboard ››

Equity Metals Corp.

Equity Metals Corp.

Equity Metals Corporation engages in the acquisition, exploration, and development of mineral properties in Canada. It ...
View More »